{"id":"5-albumin-infusion-3-hours","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Fever","drugRate":"1-2%","severity":"Mild"},{"effect":"Chills","drugRate":"1-2%","severity":"Mild"},{"effect":"Nausea","drugRate":"1-2%","severity":"Mild"},{"effect":"Headache","drugRate":"1-2%","severity":"Mild"},{"effect":"Rash","drugRate":"1-2%","severity":"Mild"}],"contraindications":["Anaphylactic shock","Severe anemia","Cardiac failure"],"specialPopulations":{"Geriatric":"Use with caution due to increased risk of fluid overload","Lactation":"Caution advised","Pediatric":"Safety and effectiveness not established","Pregnancy":"Category C - Risk cannot be ruled out"}},"trials":[],"_chembl":{"chemblId":"CHEMBL1201451","moleculeType":"Protein"},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2023-01-01","type":"Clinical","milestone":"Initiation of regional use","regulator":"Region Skane"}],"_dailymed":null,"aiSummary":"5% Albumin infusion is a plasma protein solution used primarily for volume expansion and maintenance of oncotic pressure in various clinical settings. It is administered over a period of 3 hours and is particularly useful in treating hypovolemia, hypoalbuminemia, and as a supportive therapy in critical care. The product is manufactured by Region Skane and does not have an FDA label, indicating it may be used under specific regional or hospital guidelines. Despite the lack of FDA approval, it is widely recognized for its role in stabilizing patients with fluid and protein deficiencies. The safety profile of 5% Albumin is generally favorable, but it can cause adverse reactions, which are typically mild to moderate.","ecosystem":[],"mechanism":{"target":"Intravascular volume and oncotic pressure","novelty":"Not considered novel; it is a well-established therapeutic agent","modality":"Infusion","drugClass":"Plasma expanders","explanation":"Albumin is the most abundant protein in human plasma and plays a crucial role in maintaining the colloidal osmotic pressure of blood. By increasing the concentration of albumin in the bloodstream, the infusion helps to draw fluid from the interstitial space into the vascular compartment, effectively expanding blood volume.","oneSentence":"5% Albumin infusion works by increasing intravascular volume and maintaining oncotic pressure, thereby improving blood flow and tissue perfusion.","technicalDetail":"Albumin binds to water, electrolytes, hormones, drugs, and fatty acids, and transports them through the bloodstream. Its high molecular weight and negative charge contribute to its ability to maintain oncotic pressure and prevent fluid leakage from the vasculature."},"_scrapedAt":"2026-03-28T00:17:09.528Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"Not available","launchDate":"Not available","annualCostUS":"Not available","currentRevenue":"Not available","patientPopulation":"Not available","peakSalesEstimate":"Not available"},"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":["Hypovolemia","Hypoalbuminemia","Supportive therapy in critical care"],"offLabel":["Burns","Cirrhosis with ascites","Nephrotic syndrome"],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT03174275","phase":"PHASE2","title":"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2017-12-19","conditions":"Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer","enrollment":39},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT07385001","phase":"PHASE1, PHASE2","title":"A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2026-01-28","conditions":"Esophageal Squamous Cell Carcinoma, Ivonescimab, Neoadjuvant","enrollment":45},{"nctId":"NCT07280377","phase":"PHASE1, PHASE2","title":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","status":"RECRUITING","sponsor":"Oncolytics Biotech","startDate":"2021-10-27","conditions":"Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic","enrollment":122},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT03496662","phase":"PHASE1, PHASE2","title":"BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-08-31","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":40},{"nctId":"NCT00199862","phase":"NA","title":"Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-02","conditions":"Colorectal Neoplasms, Colorectal Cancer, Colorectal Tumor","enrollment":30},{"nctId":"NCT03693677","phase":"PHASE2","title":"First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-11-16","conditions":"Metastatic Pancreatic Cancer","enrollment":288},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT03378102","phase":"EARLY_PHASE1","title":"Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Mari Dallas","startDate":"2019-01-04","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":20},{"nctId":"NCT01220154","phase":"PHASE1","title":"Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer","status":"COMPLETED","sponsor":"David O'Malley","startDate":"2011-04-28","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":9},{"nctId":"NCT06781112","phase":"PHASE2","title":"A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Weiwei Zhang","startDate":"2025-01-20","conditions":"TPF, Immunotherapy, Nasopharyngeal Carcinoma","enrollment":35},{"nctId":"NCT03678883","phase":"PHASE2","title":"9-ING-41 in Patients with Advanced Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actuate Therapeutics Inc.","startDate":"2019-01-04","conditions":"Cancer, Pancreatic Cancer, Sarcoma","enrollment":350},{"nctId":"NCT04452461","phase":"PHASE2","title":"Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery","status":"RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2021-03-01","conditions":"Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT04999761","phase":"PHASE1","title":"AB122 Platform Study","status":"RECRUITING","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2021-06-01","conditions":"Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer","enrollment":917},{"nctId":"NCT03421353","phase":"PHASE1","title":"AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-02-07","conditions":"Advanced Solid Tumours","enrollment":76},{"nctId":"NCT06542549","phase":"PHASE3","title":"Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-10-01","conditions":"Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy","enrollment":100},{"nctId":"NCT06126354","phase":"PHASE1","title":"Dexamethasone/Pancreatic Clamp P&F","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2024-07-01","conditions":"Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease","enrollment":""},{"nctId":"NCT05765084","phase":"PHASE1, PHASE2","title":"Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-02-24","conditions":"Malignant Pleural Mesothelioma","enrollment":15},{"nctId":"NCT04672005","phase":"PHASE2","title":"Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lyudmyla Berim","startDate":"2021-01-06","conditions":"Metastatic Pancreatic Cancer","enrollment":30},{"nctId":"NCT03950414","phase":"PHASE1","title":"A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2019-09-27","conditions":"Cytomegalovirus Infections, Solid Organ Transplant","enrollment":2},{"nctId":"NCT04151277","phase":"PHASE2","title":"PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"Judith Dixon-Hughes","startDate":"2017-11-28","conditions":"Neoplasms Pancreatic","enrollment":500},{"nctId":"NCT03283761","phase":"PHASE2","title":"FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Al B. Benson, III, MD","startDate":"2017-09-21","conditions":"Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer","enrollment":39},{"nctId":"NCT05101265","phase":"PHASE1","title":"Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment","status":"UNKNOWN","sponsor":"PharmaMar","startDate":"2021-03-09","conditions":"Advanced Solid Tumor, Hepatic Impairment","enrollment":24},{"nctId":"NCT06121570","phase":"PHASE1","title":"Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-11-01","conditions":"Breast Neoplasms","enrollment":24},{"nctId":"NCT05981014","phase":"PHASE1, PHASE2","title":"Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-08-01","conditions":"Breast Neoplasms","enrollment":196},{"nctId":"NCT05862168","phase":"PHASE2","title":"Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial","status":"RECRUITING","sponsor":"Weijia Fang, MD","startDate":"2023-05-08","conditions":"Oral Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT02620865","phase":"PHASE1, PHASE2","title":"BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2015-12","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer","enrollment":2},{"nctId":"NCT05738317","phase":"PHASE2","title":"Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment","status":"UNKNOWN","sponsor":"Xiaorong Dong","startDate":"2022-12-01","conditions":"Non-small Cell Lung Cancer","enrollment":45},{"nctId":"NCT05658692","phase":"PHASE4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":1000},{"nctId":"NCT03665441","phase":"PHASE3","title":"Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC","status":"COMPLETED","sponsor":"ERYtech Pharma","startDate":"2018-09-15","conditions":"Pancreatic Adenocarcinoma","enrollment":512},{"nctId":"NCT01461915","phase":"PHASE2","title":"Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2011-11","conditions":"Metastatic Pancreatic Cancer","enrollment":60},{"nctId":"NCT02810418","phase":"PHASE1, PHASE2","title":"Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-08-03","conditions":"Neoplasms, Pancreatic Neoplasms","enrollment":40},{"nctId":"NCT04089150","phase":"PHASE2","title":"MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2019-10-01","conditions":"Pancreatic Cancer","enrollment":120},{"nctId":"NCT01847001","phase":"PHASE2","title":"Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-10","conditions":"Locally Advanced Malignant Neoplasm, Breast Cancer","enrollment":10},{"nctId":"NCT02715531","phase":"PHASE1","title":"A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-04-06","conditions":"Solid Tumor","enrollment":243},{"nctId":"NCT01836432","phase":"PHASE3","title":"Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2013-05","conditions":"Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm","enrollment":302},{"nctId":"NCT03863002","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure","status":"UNKNOWN","sponsor":"Tianjin Weikai Bioeng., Ltd.","startDate":"2019-10-01","conditions":"Liver Failure, Acute on Chronic","enrollment":45},{"nctId":"NCT02911350","phase":"PHASE1","title":"Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2000-05","conditions":"Prostate Cancer","enrollment":23},{"nctId":"NCT02479581","phase":"PHASE2","title":"The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2015-07","conditions":"Valvular Heart Disease","enrollment":226},{"nctId":"NCT02728921","phase":"PHASE4","title":"The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery","status":"COMPLETED","sponsor":"Region Skane","startDate":"2014-04","conditions":"Pancreatic Neoplasms, Urogenital Neoplasm, Systemic Inflammatory Response Syndrome","enrollment":70},{"nctId":"NCT03084809","phase":"PHASE4","title":"Chemotherapy Combined With CIK Treating Colon Cancer","status":"COMPLETED","sponsor":"China Meitan General Hospital","startDate":"2012-05-06","conditions":"Colorectal Cancer, Cytokine-induced Killer Cells, Postoperative Complications","enrollment":46},{"nctId":"NCT00731380","phase":"PHASE1","title":"A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2008-07","conditions":"Head and Neck Cancer","enrollment":12},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT01057264","phase":"PHASE1","title":"HAI Abraxane With Gemcitabine and Bevacizumab","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-01","conditions":"Advanced Cancers","enrollment":78},{"nctId":"NCT02280070","phase":"PHASE2","title":"RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).","status":"UNKNOWN","sponsor":"Clinical Research Support Center Kyush","startDate":"2013-09","conditions":"Rectal Cancer","enrollment":110},{"nctId":"NCT00990509","phase":"PHASE2","title":"Albumin for Intracerebral Hemorrhage Intervention","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2009-09","conditions":"Intracerebral Hemorrhage","enrollment":14},{"nctId":"NCT00970996","phase":"PHASE1","title":"Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-09","conditions":"Melanoma","enrollment":10},{"nctId":"NCT00409383","phase":"PHASE1","title":"Abraxane and Temodar Plus Genasense in Advanced Melanoma","status":"UNKNOWN","sponsor":"Genta Incorporated","startDate":"2006-11","conditions":"Melanoma","enrollment":28},{"nctId":"NCT01254123","phase":"PHASE3","title":"Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2009-11","conditions":"Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).","enrollment":40},{"nctId":"NCT01206283","phase":"NA","title":"A Study Comparing Modified Lund Concept and Cerebral Perfusion Pressure-targeted Therapy in Secondary Brain Ischaemia.","status":"COMPLETED","sponsor":"University of Sarajevo","startDate":"2006-01","conditions":"Brain Injuries, Subarachnoid Hemorrhage","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"5% Albumin infusion 3 hours","genericName":"5% Albumin infusion 3 hours","companyName":"Region Skane","companyId":"region-skane","modality":"Small molecule","firstApprovalDate":"Not available","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}